# A Study of the Efficacy and Safety of Supaglutide in Healthy Participants

> **NCT03745885** · PHASE1 · COMPLETED · sponsor: **Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Supaglutide injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03745885
- **Lead sponsor:** Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-04
- **Primary completion:** 2019-06-10
- **Final completion:** 2019-12-13
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2021-09-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03745885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03745885, "A Study of the Efficacy and Safety of Supaglutide in Healthy Participants". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT03745885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*